ArticleMicrobial drug resistance (Larchmont, N.Y.)2022
Molecular Epidemiology of Carbapenem-Resistant
Article in Microbial drug resistance (Larchmont, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Multicenter outbreak of plasmid-encodedAntimicrobial agents and chemotherapy · 2026Article
- Comparative genomic analysis ofJAC-antimicrobial resistance · 2026Article
- High magnitude of carbapenemase-producing Acinetobacter baumannii in sepsis patients at Ethiopian referral hospitals: a whole genome analysis.Scientific reports · 2026Article
- Carbapenem-Resistant Gram-Negative Bacteria: Mechanisms, Pathogen-Specific Strategies.Infection and drug resistance · 2026Review
- Epidemiology and molecular typing of multidrug resistant Acinetobacter baumannii burn wound isolates from six Chinese provinces.Scientific reports · 2025Article
- New Delhi metallo-β-lactamase-producing Acinetobacter baumannii in the USA from October, 2013, to March, 2022: a retrospective molecular epidemiological analysis.The Lancet. Microbe · 2025Article
- Clinical burden of Acinetobacter baumannii, including carbapenem-resistant A. baumannii, in hospitalized adult patients in the USA between 2018 and 2022.BMC infectious diseases · 2025Article
- Characterization and genomic analysis of the highly virulentAntimicrobial agents and chemotherapy · 2025Article
- Longitudinal surveillance and transmission ofAntimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Neural network-based predictions of antimicrobial resistance phenotypes in multidrug-resistantAntimicrobial agents and chemotherapy · 2024Article
- Epidemiological, Phylogenetic, and Resistance Heterogeneity AmongOpen forum infectious diseases · 2024Article
- Carbapenem-resistant Acinetobacter baumannii complex in the United States-An epidemiological and molecular description of isolates collected through the Emerging Infections Program, 2019.American journal of infection control · 2024Article
- Molecular epidemiology of Acinetobacter baumannii during COVID-19 at a hospital in northern China.Annals of clinical microbiology and antimicrobials · 2024Article
- Molecular epidemiology of carbapenem-resistant gram-negative bacilli in Ecuador.BMC infectious diseases · 2024Article
- Descriptive analysis of targeted carbapenemase genes and antibiotic susceptibility profiles among carbapenem-resistantMicrobiology spectrum · 2024Article
- Epidemiology of carbapenem-resistant organisms in Alameda County, California, 2019-2021.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Molecular Epidemiology and Genetic Characterization of Carbapenem-ResistantInfection and drug resistance · 2024Article
- Acinetobacter baumannii: assessing susceptibility patterns, management practices, and mortality predictors in a tertiary teaching hospital in Lebanon.Antimicrobial resistance and infection control · 2023Observational
- Early detection of a possible multidrug-resistantIranian journal of microbiology · 2023Article
- Molecular epidemiology of Acinetobacter baumannii complex causing invasive infections in Korean children during 2001-2020.Annals of clinical microbiology and antimicrobials · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Healthcare-associated carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.